ECSP19035377A - MAGL INHIBITORS - Google Patents
MAGL INHIBITORSInfo
- Publication number
- ECSP19035377A ECSP19035377A ECSENADI201935377A ECDI201935377A ECSP19035377A EC SP19035377 A ECSP19035377 A EC SP19035377A EC SENADI201935377 A ECSENADI201935377 A EC SENADI201935377A EC DI201935377 A ECDI201935377 A EC DI201935377A EC SP19035377 A ECSP19035377 A EC SP19035377A
- Authority
- EC
- Ecuador
- Prior art keywords
- magl inhibitors
- compositions
- magl
- useful
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Se proporcionan en este documento carbamatos de piperazina y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones objeto son útiles como moduladores de MAGL. Adicionalmente, los compuestos y composiciones objeto son útiles para el tratamiento del dolor.Piperazine carbamates and pharmaceutical compositions comprising such compounds are provided herein. The subject compounds and compositions are useful as modulators of MAGL. Additionally, the subject compounds and compositions are useful for the treatment of pain.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423095P | 2016-11-16 | 2016-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19035377A true ECSP19035377A (en) | 2019-05-31 |
Family
ID=62107273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201935377A ECSP19035377A (en) | 2016-11-16 | 2019-05-17 | MAGL INHIBITORS |
Country Status (27)
Country | Link |
---|---|
US (1) | US9981930B1 (en) |
EP (1) | EP3541822B1 (en) |
JP (1) | JP6987859B2 (en) |
KR (1) | KR20190077087A (en) |
CN (1) | CN110248947B (en) |
AR (1) | AR110088A1 (en) |
AU (1) | AU2017361250A1 (en) |
BR (1) | BR112019009991A2 (en) |
CA (1) | CA3043612A1 (en) |
CL (1) | CL2019001335A1 (en) |
CO (1) | CO2019005038A2 (en) |
CR (1) | CR20190243A (en) |
DO (1) | DOP2019000121A (en) |
EA (1) | EA201991074A1 (en) |
EC (1) | ECSP19035377A (en) |
ES (1) | ES2908632T3 (en) |
IL (1) | IL266550A (en) |
JO (1) | JOP20190105A1 (en) |
MA (1) | MA46860A (en) |
MX (1) | MX2019005771A (en) |
NI (1) | NI201900050A (en) |
PE (1) | PE20191146A1 (en) |
PH (1) | PH12019501102A1 (en) |
RU (1) | RU2019116514A (en) |
TN (1) | TN2019000150A1 (en) |
TW (1) | TW201831458A (en) |
WO (1) | WO2018093946A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX350788B (en) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Carbamate compounds and of making and using same. |
KR20180004263A (en) | 2015-05-11 | 2018-01-10 | 어바이드 테라퓨틱스, 인크. | Treatment of inflammation or neuropathic pain |
EP3515897B1 (en) | 2016-09-19 | 2021-08-18 | H. Lundbeck A/S | Piperazine carbamates as modulators of magl and/or abhd6 and their use |
PL3964503T3 (en) | 2016-11-16 | 2024-04-02 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
JOP20190106A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
UA124884C2 (en) | 2016-11-16 | 2021-12-08 | Лундбек Ла Джолла Ресеарч Центер, Інк. | Pharmaceutical formulations |
JOP20190107A1 (en) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
US11142526B2 (en) | 2017-08-29 | 2021-10-12 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
AU2018361364B2 (en) * | 2017-11-02 | 2020-11-26 | Aicuris Gmbh & Co. Kg | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) |
AU2019271123A1 (en) | 2018-05-15 | 2020-11-26 | H. Lundbeck A/S. | MAGL inhibitors |
JP2023523219A (en) * | 2020-04-21 | 2023-06-02 | ハー・ルンドベック・アクチエゼルスカベット | Synthesis of monoacylglycerol lipase inhibitors |
TW202229255A (en) | 2020-11-13 | 2022-08-01 | 丹麥商H 朗德貝克公司 | A magl inhibitor |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1593586A (en) | 1967-10-17 | 1970-06-01 | ||
JPS6183073A (en) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | Paper feed method of printing apparatus |
WO1989011794A1 (en) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Plant growth inhibitor |
WO1993011097A1 (en) | 1991-11-27 | 1993-06-10 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
JPH09506920A (en) | 1993-12-22 | 1997-07-08 | シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー | Carbamate production method |
AU7579696A (en) | 1995-11-15 | 1997-06-05 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
RU2167150C2 (en) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Polyfluoroalkyl-n-arylcarbamates showing antibacterial activity |
JP2003511045A (en) | 1999-10-04 | 2003-03-25 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー | Method for identifying RNA-binding compounds |
EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
DE10348022A1 (en) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
FR2864080B1 (en) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | 1-PIPERAZINE-AND-1-HOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
JP2007523179A (en) | 2004-02-18 | 2007-08-16 | アストラゼネカ アクチボラグ | Acetylene-based piperazine compounds and their use as metabotropic glutamate receptor antagonists |
EP1740547A1 (en) * | 2004-04-07 | 2007-01-10 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
CN101830899A (en) | 2004-12-23 | 2010-09-15 | 霍夫曼-拉罗奇有限公司 | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents |
UY29321A1 (en) | 2004-12-30 | 2006-03-31 | Janssen Pharmaceutica Nv | PIPERAZINILUREAS AND PIPERIDINILUREAS AS AMID HYDROLASSES MODULATORS OF FATTY ACIDS |
JP2009523729A (en) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス,インコーポレーテッド | Treatment method for hepatitis C |
EP1987037A2 (en) | 2006-02-23 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
MX2009006706A (en) | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Bicyclic heterocyclic compounds as fgfr inhibitors. |
EP2124927A2 (en) | 2007-02-26 | 2009-12-02 | Kosan Biosciences Incorporated | Carbamate compounds |
JP2008239616A (en) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Hdl (high density lipoprotein) enhancer |
US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
US20110118286A1 (en) | 2008-07-16 | 2011-05-19 | Santhosh Francis Neelamkavil | Bicyclic heterocycle derivatives and their use as gpcr modulators |
WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
KR20110131302A (en) | 2009-03-23 | 2011-12-06 | 엠에스디 가부시키가이샤 | Novel aminopyridine derivatives having aurora a selective inhibitory action |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
EP2497082B1 (en) | 2009-11-03 | 2013-09-04 | Bayer Intellectual Property GmbH | Fluorurethane as additive in a photopolymer formulation |
FR2960875B1 (en) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
MX350788B (en) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Carbamate compounds and of making and using same. |
SG10201602862RA (en) | 2012-01-06 | 2016-05-30 | Agios Pharmaceuticals Inc | Therapeutically Active Compounds And Their Methods Of Use |
EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
US9828379B2 (en) | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
CA2979537C (en) * | 2015-03-18 | 2023-08-29 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
KR20180004263A (en) * | 2015-05-11 | 2018-01-10 | 어바이드 테라퓨틱스, 인크. | Treatment of inflammation or neuropathic pain |
US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
US10781211B2 (en) * | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
JOP20190107A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
JOP20190267A1 (en) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | Pyrazole magl inhibitors |
-
2017
- 2017-06-16 JO JOP/2019/0105A patent/JOP20190105A1/en unknown
- 2017-11-15 PE PE2019001015A patent/PE20191146A1/en unknown
- 2017-11-15 JP JP2019523589A patent/JP6987859B2/en active Active
- 2017-11-15 AR ARP170103183A patent/AR110088A1/en unknown
- 2017-11-15 MA MA046860A patent/MA46860A/en unknown
- 2017-11-15 CN CN201780083635.4A patent/CN110248947B/en active Active
- 2017-11-15 AU AU2017361250A patent/AU2017361250A1/en not_active Abandoned
- 2017-11-15 CA CA3043612A patent/CA3043612A1/en not_active Abandoned
- 2017-11-15 MX MX2019005771A patent/MX2019005771A/en unknown
- 2017-11-15 BR BR112019009991A patent/BR112019009991A2/en not_active Application Discontinuation
- 2017-11-15 KR KR1020197016859A patent/KR20190077087A/en unknown
- 2017-11-15 TN TNP/2019/000150A patent/TN2019000150A1/en unknown
- 2017-11-15 EA EA201991074A patent/EA201991074A1/en unknown
- 2017-11-15 ES ES17871883T patent/ES2908632T3/en active Active
- 2017-11-15 US US15/814,318 patent/US9981930B1/en active Active
- 2017-11-15 CR CR20190243A patent/CR20190243A/en unknown
- 2017-11-15 EP EP17871883.9A patent/EP3541822B1/en active Active
- 2017-11-15 WO PCT/US2017/061867 patent/WO2018093946A1/en active Application Filing
- 2017-11-15 RU RU2019116514A patent/RU2019116514A/en not_active Application Discontinuation
- 2017-11-16 TW TW106139750A patent/TW201831458A/en unknown
-
2019
- 2019-05-12 IL IL266550A patent/IL266550A/en unknown
- 2019-05-16 PH PH12019501102A patent/PH12019501102A1/en unknown
- 2019-05-16 DO DO2019000121A patent/DOP2019000121A/en unknown
- 2019-05-16 CL CL2019001335A patent/CL2019001335A1/en unknown
- 2019-05-16 CO CONC2019/0005038A patent/CO2019005038A2/en unknown
- 2019-05-16 NI NI201900050A patent/NI201900050A/en unknown
- 2019-05-17 EC ECSENADI201935377A patent/ECSP19035377A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20180134675A1 (en) | 2018-05-17 |
JP6987859B2 (en) | 2022-01-05 |
MX2019005771A (en) | 2019-12-05 |
PE20191146A1 (en) | 2019-09-02 |
BR112019009991A2 (en) | 2019-08-27 |
AU2017361250A1 (en) | 2019-05-30 |
TW201831458A (en) | 2018-09-01 |
ES2908632T3 (en) | 2022-05-03 |
AR110088A1 (en) | 2019-02-20 |
CN110248947A (en) | 2019-09-17 |
WO2018093946A1 (en) | 2018-05-24 |
CA3043612A1 (en) | 2018-05-24 |
JP2020502047A (en) | 2020-01-23 |
CN110248947B (en) | 2022-04-01 |
KR20190077087A (en) | 2019-07-02 |
RU2019116514A (en) | 2020-12-17 |
IL266550A (en) | 2019-07-31 |
EA201991074A1 (en) | 2019-12-30 |
EP3541822B1 (en) | 2022-01-19 |
EP3541822A1 (en) | 2019-09-25 |
CO2019005038A2 (en) | 2019-05-31 |
CL2019001335A1 (en) | 2019-10-04 |
TN2019000150A1 (en) | 2020-10-05 |
MA46860A (en) | 2019-09-25 |
DOP2019000121A (en) | 2019-09-30 |
EP3541822A4 (en) | 2020-04-29 |
JOP20190105A1 (en) | 2019-05-09 |
NI201900050A (en) | 2019-10-30 |
PH12019501102A1 (en) | 2019-08-19 |
US9981930B1 (en) | 2018-05-29 |
CR20190243A (en) | 2019-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000122A (en) | MAGL INHIBITORS | |
ECSP19035377A (en) | MAGL INHIBITORS | |
CO2019000386A2 (en) | Heterocyclic compounds as immunomodulators | |
CL2018001685A1 (en) | Heterocyclic compounds as immuno modulators. | |
NI202000080A (en) | MAGL INHIBITORS | |
ECSP19083923A (en) | MAGL PYRAZOLIC INHIBITORS | |
NI201900049A (en) | MAGL INHIBITORS | |
CL2016003246A1 (en) | Compounds of substituted dihydroisoquinolinone | |
CL2019003397A1 (en) | Pyrazole magl inhibitors. | |
CL2019002583A1 (en) | Dual inhibitors of magl and faah. | |
CR20190028A (en) | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |